Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up

American Journal of Hematology

Volumn 85, Issue 5, 2010, Pages 375-377

  Breccia, Massimo ^a   Stagno, Fabio ^b   Vigneri, Paolo ^b   Latagliata, Roberto ^a   Cannella, Laura ^a   Del Fabro, Vittorio ^b   Di Raimondo, Francesco ^b   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; GENETIC RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; PERIPHERAL EDEMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; YOUNG ADULT;

EID: 77951557996     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21680     Document Type: Article

References (12)

1. Baccarani M, Saglio G, Goldman J, et al. European leukemia net. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006; 108:1809-1820.
2. Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 2008;93:161-169.
3. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114: abst 1126
4. Apperley JF. Part 1: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-1029. (Pubitemid 47629897)
5. Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007;249:121-132. (Pubitemid 46452920)
6. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 2007;44:S15-S24. (Pubitemid 46209243)
7. Kantarjian HM, Larson RA, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) investigators efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115: 551-560.
8. Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003;102: 2702-2703. (Pubitemid 37193621)
9. Zonder JA, Pemberton P, Brandt H, et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092-2097. (Pubitemid 36687630)
10. Jabbour E, Kantarjian H, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113: 2154-2160.
11. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-475. (Pubitemid 36077567)
12. Rea D, Etienne G, Corm S, et al. Imatinib dose escalation for chronic phasechronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy. Leukemia 2009;23:1193-1196.